申请人:Max-Planck-Gesellschaft zur Förderung der
Wissenschaften e.V.
公开号:EP2532664A1
公开(公告)日:2012-12-12
The present invention relates to novel substituted indolo [2,3-a] quinolizines of the general formula (I)
and stereoisomeric forms thereof and/or pharmaceutically acceptable salts of these compounds as well as pharmaceutical compositions containing at least one of these substituted indolo [2,3-a] quinolizines together with pharmaceutically acceptable carrier, excipient and/or diluents. Said novel substituted indolo [2,3-a] quinolizines have been identified as useful for the prophylaxis and treatment of cancer by the induction of strong mitotic delays, chromosomal misalignments and mitotic tri- and multipolarization leading to cell cycle stop and apoptosis. Furthermore a synthesis for preparation of the substituted indolo [2,3-a] quinolizines is disclosed in the present invention.
本发明涉及新颖的取代吲哚[2,3-a]喹啉化合物,其一般式为(I),以及其立体异构体和/或这些化合物的药学上可接受的盐,以及含有至少一种这些取代吲哚[2,3-a]喹啉的药物组合物,其中还包括药学上可接受的载体、赋形剂和/或稀释剂。所述的新颖取代吲哚[2,3-a]喹啉已被确定为用于预防和治疗癌症的有用药物,通过诱导强烈的有丝分裂延迟、染色体错位和有丝分裂三价和多价化导致细胞周期停滞和凋亡。此外,本发明还公开了一种用于制备取代吲哚[2,3-a]喹啉的合成方法。